Medical treatment of diabetes type 2 - Recommendation for good practice;Traitement médicamenteux du diabète de type 2 - Recommandation de bonne pratique

Diabetes and Metabolism

Volumn 33, Issue 1 SUPPL. PART 2, 2007, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; BIGUANIDE; GLIBENCLAMIDE; GLIPIZIDE; GLUCOR; INSULIN ZINC SUSPENSION; METFORMIN; METFORMIN EMBONATE; MIGLITOL; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG ABSORPTION; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; REIMBURSEMENT;

EID: 34248187199     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)80038-3     Document Type: Note

References (484)

1. Simon D., Fagot-Campagna A., Eschwège E., and Balkau B. Définition, dépistage et épidémiologie du diabète. In: Grimaldi A. (Ed). Traité de diabétologie. Flammarion (2005), Médecine-Sciences, Paris
2. Alberti K.G.M.M., Zimmer P.Z., and WHO C. Definition, diagnosis and classification of diabetes mellitus and its complications, Part I. Diagnosis and classification of diabetes mellitus.Provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
3. Grundy S.M., Brewer H.B., Cleeman J.I., et al. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 109 (2004) 433-438
4. The European Group for the study of insulin resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 28 (2002) 364-376
5. International Diabetes Federation: http://www.idf.org/webdata/docs/IDF_Metasyndrome definition.pdf
6. Ricordeau P., Weill A., Vallier N., et al. Prévalence et coût du diabète en France métropolitaine: quelles évolutions entre 1998 et 2000?. Revue Médicale de l'Assurance maladie 33 (2002) 257-265
7. Detournay B., Raccah D., Cadilhac M., and Eschwège E. Epidemiology and costs of diabetes treated with insulin in France. Diabetes Metab 31 (2005) 251-2518
8. Favier F., Jaussent I., Le Moullec N., et al. Prevalence of type 2 diabetes and central obesity in La Réunion Island, the REDIA study. Diabetes Research and Clinical Practice 67 (2005) 234-242
9. CNAM : www.ameli.fr
10. Hirtzlin I., Fagot-Campagna A., Girard-Le Gallo I., et al. Dépistage du diabète: les données de l'échantillon permanent des Assurés Sociaux, 2000-2001. Rev Epidemiol Santé Publique 52 (2004) 119-126
11. c enquête épidémiologique nationale sur l'obésité et le surpoids en France. Enquête épidémiologique INSERM, Institut Roche de l'Obésité, TNS-SOFRES.
12. Numéro spécial. BEH 2003 Surveillance du diabète. étude ENTRED : bilan d'étape. BEH 49-50 (2003) 237-244
13. Numéro thématique. www.invs.sante.fr/entred. fr. BEH 12-13 (2005) 45-52
14. BEH 2006;mars. Fosse S., Jacqueminet S.A., Hartemann-Heurtier A., et al. Incidence et caractéristiques des amputations de membres inférieurs chez les personnes diabétiques en. France métropolitaine 10 (2003) 71-73
15. Étude EUROASPIRE. Pyorala K., Lehto S., De Bacquer D., De Sutter J., Sans S., Keil U., Wood D., and De Backer G. EUROASPIRE I Group; EUROASPIRE 11 Group.Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from theEUROASPIRE I AND II surveys. Diabetologia 47 (2004) 1257-1265
16. Étude CODE-2. Jonsson B. CODE-2 Advisory Board. Revealing the cost of Type II diabetes in Europe. Diabetologia 45 (2002) S5-512
17. bis. Étude CODE-2 France. Detournay B., Fagnani F., Pribil C., and Eschwège E. Code 2: Medical resources consumption of type 2 diabetics in France in 1998. Diabetes & Metabolism 26 (2000) 225-231
18. Étude CRESGE-LABORES. Marissal J.P., Sailly J.C., Crainich D., and Lebrun T. Assessment of the macroeconomic impact of treatment guidelines in type II diabetes mellitus in France. Rev Epidemiol Saute Publique 53 (2005) 1567-1578
19. Carpentier B., Pradines S., Benhamou P.Y., and Halimi S. Health costs associated with the diabetic foot in developed countries. Aplea for the creation of health care networks. Diabetes Metab 20 (2000) 75-80
20. The Expert Committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classificationof diabetes mellitus. Diabetes Care 20 (1997) 1183-1197
21. Alberti K.G.M.M., Zimmet P.Z., and WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Diabet Med 15 (1998) 539-553
22. Fajans S.S., Bell G.I., and Polonsky K.S. Molecular mechanisms and clinical pathophysiology of Maturity-onset diabetes of the young. N Engl J Med 345 (2001) 971-980
23. Guillausseau P.J., Massin P., Dubois-Laforgue D., et al. Maternally Inherited Diabetes and Deafness: A multicenter Study. Ann Intern Med 134 (2001) 721-728
24. Polonsky K.S., Sturis J., Bell G.I., et al. Non-insulin-dependent diabetes mellitus. A genetically programmed failure of the beta-cell to compensate for insulin resistance. N Engl J Med 334 (1996) 777-783
25. Elbein S.C., Wegner K., and Kahn S.E. Reduced β-cell compensation to the insulin resistance associated with obesity in members of Caucasian familial type 2 diabetic kindreds. Diabetes Care 23 (2000) 221-227
26. Guillausseau P.J. Anomalie de l'insulinosécrétion et diabète de type 2 données récentes. Diabetes Metab 20 (1994) 325-329
27. Bergsten P. Pathophysiology of impaired pulsatile insulin release. Diabetes Metab Res Rev 16 (2000) 179-191
28. Paolisso G., Scheen A.J., Giugliano D., et al. Pulsatile insulin delivery has greater metabolic effect than continuous hormon administration in man: importance of pulse frequency. J Clin Endocrinol Metab 72 (1991) 607-615
29. Bratush-Marrain P.R., Komjati M., and Waldhausl W.K. Efficacy of pulsatile versus continuous insulin administration on hepatic glucose production and glucose utilization in type 1 diabetic humans. Diabetes 35 (1986) 922-926
30. Trump B.E., and Berezesky I.K. Calcium-mediated injury and cell death. FASEB J 9 (1995) 219-223
31. Polonsky K.S., Given B.D., Hirsch L.J., et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 318 (1988) 1231-1239
32. O'Meara N.M., Sturis J., Van Cauter E.V., and Polonsky K.S. Lack of control of ultradian insulin secretioy oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus. J Clin Invest 92 (1993) 262-271
33. O'Rahify S., Turner R.C., and Matthews D.R. Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N Engl J Med 318 (1988) 1225-1230
34. Cerasi E., and Luft R. The plasma insulin response to glucose infusion in healthy subjects and in diabetes mellitus. Acta Endocrinol (Kbh) 55 (1967) 278-304
35. Fujita Y., Herrow A.L., and Seltzer H.S. Confirmation of impaired early insulin response to glycemic stimulus in non obese mild diabetes. Diabetes 24 (1975) 17-27
36. Metz S.A., Halter J.B., and Robertson R.P. Paradoxical inhibition of insulin secretion by glucose in human diabetes mellitus. J Clin Endocrinol Metab 48 (1979) 827-835
37. Pfeiffer M.A., Halter J.B., and Porte D. Insulin secretion in diabetes mellitus. Am J Med 70 (1981) 579-588
38. Brunzell J.D., Robertson R.P., Lerner R.L., et al. Relationship between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 42 (1976) 222-229
39. Ratzmann K.P., Schulz B., Heinke P., et al. Quantitative and qualitative changes in the early insulin response to glucose in subjects with impaired carbohydrate tolerance. Diabetes Care 4 (1981) 85-91
40. Eriksson J., Franssila-Kafunki A., Ekdtrand A., et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 321 (1989) 337-343
41. Sobey F.W.J., Beer S.F., Carrington C.A., et al. Sensitive and specific twosite immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochem J 260 (1989) 535-541
42. Temple R.C., Carrington G.A., Luzio S.D., et al. Insulin deficiency in non-insulin-dependent diabetes. Lancet 1 (1989) 293-295
43. DavieS M.J., Metcalfe J., Gray I.F., et al. Insulin deficiency rather than hyperinsulinemia in newly diagnosed type 2 diabetes mellitus. Diabetic Med 10 (1993) 305-312
44. Temple R.C., Clark P.M.S., Nagi D.K., et al. Radio immunoassay may overestimate insulin in non-insulin-dependent diabetics. Clin Endocrinol 32 (1990) 689-693
45. Wang P.W., Abbasi F., Carantoni M., et al. Insulin resistance does not change the ratio of proinsulin to insulin in normal volunteers. J Clin Endocrinol Metab 82 (1997) 3221-3224
46. Kruszynska Y.T., Harry D.S., Mohamed-Ali V., et al. The contribution of proinsulin and des 31-32 proinsulin to the hyperinsulinemia of diabetic and non diabetic cirrhotic patients. Metabolism 44 (1995) 254-260
47. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years therapy of type 11 diabetes: a progressive disease. Diabetes 44 (1995) 1249-1258
48. Purrello F., and Rabuazzo A.M. Metabolic factors that affect β-cell function and survival. Diab Nutr Metab 13 (2000) 84-91
49. Rossetti L., Giaccari A., and De Fronzo R.A. Glucose toxicity. Diabetes Care 13 (1990) 610-630
50. Unger R.H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes 44 (1995) 863-870
51. Olson K.L., Redmon J.B., Towle H.C., et al. Chronic exposure of HIT cells to high glucose concentrations paradoxically decreases insulin gene transcription and alters binding of insulin gene regulatory proteins. J Clin Invest 92 (1993) 514-519
52. Matsuoka T., Kajimoto Y., Wataka H., et al. Glycation-dependent, reactive oxygen-species-mediated suppression of the insulin gene promoter activity in HIT cells. J Clin Invest 99 (1997) 144-150
53. Sakuraba H., Mizukami H., Yagihashi N., et al. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islets of Japanese type Il diabetic patients. Diabetologia 45 (2002) 85-96
54. Höppener J.W.H., Ahren B., and Cornelis J.M. Islet amyloid and type 2 diabetes mellitus. N Engl J Med 343 (2000) 411-419
55. De Fronzo R.A. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5 (1997) 177-246
56. Elbein S.C. An update on the genetic basis of type 2 diabetes. Curt Opin Endocrinol Diab 5 (1998) 116-125
57. Hales C.N., Barker D.J.P., Clark P.M.S., et al. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ 303 (1991) 1019-1022
58. Garofano A., Czernichow P., and Breant B. In utero undernutrition impairs rat beta-cell development. Diabetologia 40 (1997) 1231-1234
59. Gerich J.E. Insulin resistance is not necessarily an essential component of type 2 diabetes. J Clin Endocrinol Metab 85 (2000) 2113-2115
60. Wingard D.L., Sinsheimer P., Barret-Connor E.L., et al. Communitybased study of prevalence of NIDDM in older adults. Diabetes Care 13 suppl. 2 (1990) 3-8
61. Pan X.R., Li G.W., Hu Y.H., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study. Diabetes Care 20 (1997) 537-544
62. Tuomilheto J., Lindström J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engt J Med 344 (2001) 1343-1350
63. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
64. Kahn B.B., and Flier J.S. Obesity and insulin resistance. J Clin Invest 106 (2000) 473-481
65. Shulman G.I. Cellular mechanisms of insulin resistance. J Clin Invest 106 (2000) 171-176
66. Kahn C.R. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 43 (1994) 1066-1084
67. Gerich J.E. Insulin resistance is not necessarily an essential component of type 2 diabetes. J Clin Endocrinol Metab 85 (2000) 2113-2115
68. Weyer C., Bogardus C., Mott D.M., et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104 (1999) 787-797
69. Henriksen J., Alford F., Ward G., et al. Risk and mechanism of dexamethasone induced deterioration of glucose tolerance in non-diabetic first degree relatives of NIDDM patients. Diabetologia 40 (1997) 143-948
70. Roder M.E., Schwartz R.S., Prigeon R.L., et al. Reduced pancreatic β-cell compensation to the insulin resistance ofaging: impact on proinsulin and insulin levels. J Clin Endocrinol Metab 85 (2000) 2275-2280
71. O'Rahilly S., Nugent G., Rudenski A.S., et al. 52.-cell dysfunction, rather than insulin-insensitivy, is the primary defect in familial type 2 diabetes. Lancet 2 (1986) 360-364
72. Larsson H., and Ahren B. Islet dysfunction in obese women with impaired glucose tolerance. Metabolism 45 (1996) 502-509
73. Eriksson J., Franssila-Kallunki A., Ekdtrand A., et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 321 (1989) 337-343
74. Mitrakou A., Kelly D., Mokan M., et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326 (1992) 22-29
75. Pimenta W., Korytkowski M., Mitrakov A., et al. Pancreatic beta-cell dysfunction as the primary genetic lesion of NIDDM. JAMA 273[pp1855-1861 (1995)
76. Martin B.C., Warram J.H., Krolewski A.S., et al. Role of glucose and insulin resistance in development of type 2 diabetes metlitus: results of a 25-year follow-up study. Lancet 340 (1992) 925-929
77. Warram J.H., Martin B.C., Krolewski A.S., et al. Slow glucose removal rate and hyperinsulinemia precede the development of type lI diabetes in the offspring of diabetic parents. Ann Intern Med 113 (1990) 909-915
78. Lillioja S., Mott D.M., Howard B.V., et al. Impaired glucose tolerance as a disorder of insulin action. N Engl J Med 318 (1988) 1217-1225
79. Lilhoja S., Mott D.M., Spraul M., et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med 329 (1993) 1988-1992
80. Haffner S.M., Miettinen H., Gaskill S.P., et al. Decreased insulin secretion and increased insulin resistance and independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes 44 (1995) 1386-1391
81. Dunn C., and Peters D. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49 (1995) 721-749
82. Dornan T., Heller S., Peck G., and Tattersall R. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care 14 (1991) 342-344
83. Goodman A. Efficacy and safety of metformin in NIDDM. Diabetes 42 (1993) 57A
84. Nagi D., and Yudkin J. Effects of metformin on insuline resistance, risk factors for cardiovascular disease and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 16 (1993) 621-629
85. De Fronzo R., Goodman A., and The multicenter metformin study group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333 (1995) 541-549
86. Grant P. The effects of high and medium dose metformin therapy on cardiovascular risk factors in patients with type 11 diabetes. Diabetes Care 19 (1996) 64-66
87. Campbell I., and Hewlett C. World wide experience of metformin as an effective glucose lowering agent: a metaanalysis. Diabetes Metabolism Review 11 (1995) S57-S62
88. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
89. Gregorio F., Ambrosi F., Marchetti P., et al. Low-dose metformin in the treatment of type II non insulin-dependent diabetes : clinical and metabolic evaluations. Acta Diabetol Int 27 (1990) 139-155
90. Marena S., Tabliaferro V., Montegrosso G., et al. Metabolic effects of metformin addition to chronic glibenclamide treatment in type II diabetes. Diabetes Metab 20 (1994) 15-19
91. Groop L., and Widen E. Treatment strategies for secondary sulfonyl-urea failure. Diabetes Metab 17 suppl 1 (1991) 218-223
92. Klein W. Sulfonyl-urea combination versus sulfonyl-insulin combination in secondary failures of sulfonyl-urea monotherapy. Diabetes Metab 17 (1991) 235-240
93. Guigliano D., Quatrano A., and Consoli G. Metformin for obese insulintreated diabetic patients: improvement in glycemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 44 (1993) 107-112
94. Campbell I. Metformin and the sulphonyl-ureas: the comparative risk. BMJ 289 (1984) 105-111
95. Gan S., Barr J., and Aireff A. Biguanide associated lactic acidosis: case report and review of litterature. Arch Intern Med 152 (1992) 2333-2336
96. Wilhelm B., and Myrhed M. Metformin-associated lactic acidosis in Sweden 1977-1991. Eur J Clin Pharmacol 44 (1993) 589
97. Aguilar C., Reza A., Garcia E., and Roll J. Biguanide related lactic acidosis: incidence and risk factors. Arch of Medical Research 23 (1992) 19-24
98. Salpeter S., Greyber E., Pasternak G., and Salpeter E. Risk of fatal and non fatal lactic acidosis with metformin in type 2 diabetes mellitus. The Cochrane Library Issue 1 (2003)
99. Cryer D.R., Nicholas S.P., David H., Henry D.H., et al. Comparative outcomes study of metformin intervention versus conventional approach. The COSMIC Approach Study. Diabetes Care 28 (2005) 539-543
100. Holstein A., and Stumvoll M. Contraindications can damage your healthis metformine a case in point?. Diabetologia 48 (2005) 2454-2459
101. Eurich D.T., Majumdar S.R., McLister F.A., et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28 (2005) 2345-2351
102. Inzucchi S.E. Metformin and heart failure. Diabetes Care 28 (2005) 2585-2587
103. Melander A. Oral anti-diabetic drugs: an overview. Diabetic Medicine 13 (1996) S143-S147
104. Ilarde A., and Tuck M. Treatment of non insulin-dependent diabetes mellitus and its complications. A state of the art review. Drugs and Aging 4 (1994) 470-491
105. UKPDS Group. Relative efficacy of randomly allocated diet, sulphonyl-urea, insulin or metformin in newly diagnosed non-insulin dependent diabetes followed for 3years (UKPDS 13). BMJ 310 (1995) 83-90
106. Rosenstock J., Samols E., Muchmore D., et al. Glimepiride, a new once daily sulfonyl-urea. A double blind placebo controlled study of NIDDM patients. Diabetes Care 19 (1996) 1194-1199
107. Simonson D., Kourides I., Feinglos M., et al. Efficacy, safety and dose response characteristics of glipizide gastro-intestinal therapeutic system on glycemic control and insulin secretion inNIDDM. Diabetes Care 20 (1997) 597-606
108. (suppl). Tsumura K. Clinical evaluation ofglimepiride (HOE 490) in NIDDM including a double- blind comparative study versus gliclazide. Diabetes Research and Clinical Practice 28 (1995) S147-S149
109. Draeger K., Wernicke P.K., et al. Long-term treatment of type 2 diabetic patients with the new oral anti-diabetic agent glimepiride (Amaryl®): a double-blind comparison withglibenclamide. Horm Metab Res 28 (1996) 419-425
110. Dills D., and Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res 28 (1996) 426-429
111. UKPDS Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
112. UKPDS Group. Sulfonyl urea failure in non insulin-dependent diabetic patients over six years. (UKPDS 26). Diabetic Medicine 15 (1998) 297-303
113. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
114. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression ofdiabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6 year study. Diabetic Research and Clinical Practice 28 (1995) 103-117
115. Pontiroli A., Calderrara A., and Pozza Y. Secondary failure of oral hypoglycemic agents. Frequency, possible causes and management. Diabetes Metabolism Review 10 (1994) 31-43
116. Wolffenbuttel B., and Van Haeften T. Prevention ofcomplications in noninsulin-dependent diabetes mellitus. Drugs 50 (1995) 263-288
117. Alberti K., and Gries F. Management of non-insulin-dependent, diabetes in Europe: a consensus view. Diabetic Medicine 5 (1988) 275-281
118. Campbell I. Metformin and the sulphonyl-ureas: the comparative risk. BMJ 289 (1984) 105-111
119. Harrower A. Pharmacokinetics of oral antihyperglycemic, agents in patients with renal insufficiency. Clin Pharmacol 31 (1996) 111-119
120. Owens D.R., Luzio S.D., Ismail I., et al. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care 23 (2000) 518-523
121. Goldberg R.B., Einhorn D., Lucas C.P., et al. A randomized placebocontrolled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 21 (1998) 1897-1903
122. Jovanovic L., Dailey III G., Huang W.C., et al. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. Clin Pharmacol 40 (2000) 49-57
123. Van Gaal L.E., Van Acker Kl., and De Leeuw I.H. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes. Diabetes Res Clin Pract 53 (2001) 141-148
124. Moses R.G., Gomis R., Frandsen K.B., et al. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care 24 (2001) 11-15
125. Landgraf R., Bilo H.J.G., and Müller P.G. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 55 (1999) 165-171
126. Marbury T., Huang W.C., Strange P., et al. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 43 (1999) 155-166
127. Wolffenbuttel B.H.R., and Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Diabetes Care 22 (1999) 463-467
128. Madsbad S., Kilhovd B., Lager I., et al. Comparison between repaglinide and glipizide in type 2 diabetes mellitus: a 1-year multicentre study. Diabetic Medicine 18 (2001) 395-401
129. Moses R., Slobodniuk R., Boyages S., et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 22 (1999) 119-124
130. Damsbo P., Clauson P., Marbury T., et al. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 22 (1999) 789-794
131. Schumacher S., Abbasi I., Weise D., et al. Single-and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 57 (2001) 147-152
132. Hasslacher for the multinational repaglinide renal study group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 26 (2003) 886-891
133. Niemi M., Backman J.T., Neuvonen M., et al. Effects of gemfibrozil, itraconazole and their combination on the pharmacokinetics and pharmacodynamics of repaglinide potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46 (2003) 347-351
134. Agence Française de Sécurité Sanitaire des Produits de Santé (Afssaps). Contre-indication de l'association répaglinide (NovoNorm®) et gemfibrozil (Lipur®) (22 mai 2003), Communiqué de presse du
135. Reuser A., and Wisselaar H. An evaluation of the potential side-effects of alphaglucosidase inhibitors used for the management of diabetes mellitus. Eur J Clin Invest 24 suppl 3 (1994) 19-24
136. Toeller M. Alphaglucosidase inhibitors in diabetes: efficacy in NIDDM. Eur J Clin Invest 24 suppl 3 (1994) 31-35
137. Hanefeld M., Fischer S., and Schulze J. Therapeutical potentials of acarbose as first live drug in non-insulin-dependent diabetes insufficiently treated with died alone. Diabetes Care 14 (1991) 732-737
138. Innerfield R., and Coniff R. A multicenter double-blind, placebo-controlled study of the long-term efficacy and safety of acarbose (BAY g 5421) in the treatment of obese patients uncontrolled by diet alone. Diabetes 39 (1990) 211 A
139. Hotta N., Kakuta H., Sano T., et al. Long-term effect of acarbose on glycemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. Diabetic Medicine 10 (1993) 134-138
140. Gotto Y, Nakagawa S, Orimo H, et al. Clinical efficacy of BAY g 5421(acarbose) in non-insulin dependent diabetes mellitus. In Lefèbvre PJ, Standl E Eds. New aspects in diabetes. Berlin.
141. Coniff R., Shapiro A., and Seaton T. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch intern Med 154 (1994) 2442-2448
142. Chiasson J.C., Josse R., Hunt J., et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicente controlled clinical trial. Annals Intern Med 121 (1994) 928-935
143. Braun D., Schönherr U., and Mitzkat Hl. Efficacy of acarbose monotherapy in patients with type 2 diabetes: a double-blind study inducted in general practice. Endocrinology and Metabolism 6 (1996) 275-280
144. (suppl). Hoffman J., and Splengler M. Efficacy of 24 week mono-therapy with acarbose, metformin or placebo in NIDDM patients with dietary failure. Diabetologia 39 (1996) 873
145. Johnston P., Feig P., Coniff R., et al. Chronic treatment of african-american type II diabetic patients with alpha-glucosidase inhibition. Diabetes Care 21 (1998) 416-422
146. Johnston P., Coniff R., Hoogwert B., et al. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 17 (1994) 20-29
147. Josse R.G., Chiasson J.L., Ryan E.A., et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Research and Clinical Practice 59 (2003) 37-42
148. Johnston P., Coniff R., Hoogwert B., et al. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 17 (1994) 20-29
149. Schwedes U., Petzeldt R., Hillebrand I., and Schöffling K. Comparison of acarbose and metformin treatment in non-insulin-dependent diabetic out-patients. In: Creutzfeldt W. (Ed). Proceedings of the first interna tional symposium on acarbose (1982), Excepta Mediea, Amstderdam 275-281
150. Mies R., and Spengler M. Efficacy of the glucosidase inhibitor acarbose compared to the sulfonyt-urea glisoxepid on metabolic control of type 2 diabetes. Diabetologia 30 (1987) 557A
151. Spengler M., Hänsel G., and Boehmeke K. Acarbose and Glibenclamid bei type II Diabetes. Zfür Allgemeine Medizin 66 (1990) 606-610
152. Fölsch U., Spengler M., Boehme K., and Sommerauer B. Efficacy of glucosidase inhibitors compared to sulfonyl-ureas in the treatment and metabolic control of diet treated type II diabetic subjects: twolong term comparative studies. Diab Nutr Metab 3 suppl 1 (1990) 63-68
153. Pagano G., Marena S., Corgiat-Mansin L., et al. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. Diabetes Metab 21 (1995) 162-167
154. Segal P., Feig P.U., Schernthaner G., et al. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care 20 (1997) 687-691
155. Salman S., Salman F., Satman I., et al. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. Current Medical Research & Opinion 16 (2001) 296-306
156. Halimi S., Le Bette M.A., and Grange V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin:a double-blind, pla cebo-controlled study. Diabetes Research & Clinical Practice 50 (2000) 49-56
157. Willms B., and Ruge D. Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabetic Medicine 16 (1999) 755-761
158. Chiasson J.C., Josse R., Hunt J., et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicente controlled clinical trial. Annals Intern Med 121 (1994) 928-935
159. Holman R.R., Cull C.A., Turner R.C., et al. A randomized double-blind trial of acarbose in Type 2 diabetes shows improved glycemic control over 3 years (UK PDS 34). Diabetes Care 22 (1999) 960-964
160. Hanefeld M., Cagatay M., Petrowitsck T., et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25 (2004) 10-16
161. Van De Laar F.A., Lucassen P.L., Akkermans R.P., et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes. Diabetes Care 28 (2005) 166-175
162. Reuser A., and Wisselaar H. An evaluation of the potential side-effects of alphaglucosidase inhibitors used for the management of diabetes mellitus. Eur J Clin Invest 24 suppl 3 (1994) 19-24
163. Fonseca V., Rosenstock J., Patwardhan R., et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. A randomized controlled trial. JAMA 283 (2000) 1695-1702
164. Wolffenbuttel B.H.R., Gomist R., Squatrito S., et al. Addition of lowdose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabetic Medicine 17 (2000) 40-47
165. Gomez-Perez F.J., Fanghanel-Salmon G., Barbosa A., et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 18 (2002) 127-134
166. Barnett A.M., Grant P.J., Hitman G.A., et al. Rosiglitazone in type 2 diabetes mellitus: an evaluation in British Indo-Asian patients. Diabet Med 20 (2003) 387-393
167. Kipnes M.S., Krosnick A., Rendell M.S., et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 111 (2001) 10-17
168. Einhorn D., Rendell M., Rosenzweig J., et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The pioglitazone 027 study group. Clinical Therapeutics 22 (2000) 1395-1409
169. Raskin P., McGill J., Saad M.E., et al. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone. Diabet Med 21 (2004) 329-335
170. Lebovitz H.E., Dole J.O.E., Patwardhan R., et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86 (2001) 280-288
171. Phillips L.S., Grunberger G., Miller E., et al. Once- and twice daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabtes Care 24 (2001) 308-315
172. Aronoff S., Rosenblatt S., Braithwaite S., et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. A 6-month randomized placebo-controlled dose-response study. Diabetes Care 23 (2000) 1605-1611
173. Rosenblatt S., Miskin B., Glazer N.B., et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 12 (2001) 413-423
174. Yamanouchi T., Sakai T., Igarashi K., et al. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabet Med 22 (2005) 980-985
175. Raskin P., Rendell M., Riddle M.C., et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 24 (2001) 1226-1232
176. Rosenstock J., Einhorn D., Hershon K., et al. Efficacy and safety of pioglitazone in type 2 diabetes: a randomized, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 56 (2002) 251-257
177. Khan M.A., St. P.J.V., and Xue J.L. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previouslytreated with troglitazone. Diabetes Care 25 (2002) 708-711
178. Daily G.E., Noor M.A., Jung Soon P., et al. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med 116 (2004) 223-229
179. Aljabri K., Kozak S.E., and Thomson D.M. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: aprospective, randomized trial. Am J Med 116 (2004) 230-235
180. Rosenstock J., Sugimoto D., and Strange P. Triple therapy in type 2 diabetes. Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïvepatients. Diabetes Care 29 (2006) 554-559
181. Delea T.E., Edelsberg J.C., Agiwara M., et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes. A retrospective study. Diabetes Care 26 (2003) 2983-2989
182. Betteridge D.J., and Vergès B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia 48 (2005) 2477-2481
183. Charbonnel B., Dormandy I., Erdmann E., et al. The Prospective
184. Dormandy J.A., Charbonnel B., Eckland D.J.A., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomiserd controlled trial. Lancet 366 (2005) 1279-1289
185. Goldberg R.B., Kendall D.M., Deeg M.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
186. Nesto R.W., Bell D., Bonow K.O., et al. Thiazolidinedione use, fluid retention and congestive heart failure. Circulation 108 (2003) 2941-2948
187. Lebovitz H.E., Kreider M., and Freed M.I. Evaluation of liver function in type 2 diabetic patients during clinical trials. Evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 25 (2002) 815-821
188. Forman L.M., Simmons D.A., and Diamond R.H. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 132 (2000) 118-121
189. Al-Salman J., Arjomand H., Kemp D.G., et al. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med 132 (2000) 121-124
190. May L.D., Lefkowitch J.H., Kram M.T., et al. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 136 (2002) 449-452
191. Pinto A.G., Cummings O.W., and Chalasani N. Severe but reversible cholestatic liver injury after pioglitazone therapy. Ann Intern Med 137 (2002) 857
192. Nagasaka S., Abe T., and Kawamaki A. Pioglitazone-induced hepatic injury in apatient previously receiving troglitazone with sucess. Diabet Med 19 (2002) 347-348
193. In: Farley-Hills, Sivasankar R., and Martin M. (Eds). Fatal liver failure associated with pioglitazone. BMJ 329 (2004) 429
194. Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophtalmol 123 (2005) 1273-1275
195. Hirsch Irl B. Insulin analogues. N Engl J Med 352 (2005) 174-183
196. Issue 2. Siebenhofer A., Plank J., Berghold A., Narath M., Gfrer R., and Pieber T.R. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus (Cochrane review). The Cochrane Library (2004), John Wiley & Sons, Ltd., Chichester, UK
197. McKeage K., and Goa K.L. Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. Drugs 61 (2001) 1599-1624
198. Yki-Järvinen H.D., Dressler A., and Zieme M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulincombination therapy in type 2 diabetes. Diabetes Care 23 (2000) 1130-1136
199. Rosenstock J., Schwartz S.L., and Clark C.M. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24 (2001) 631-636
200. Riddle C.M., Rosenstock J., Gerich J., et al. The Treat-to target trial. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
201. Fritsche A., Schweitzer M.A., and Häring H.U. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagendorn insulin or bedtime insulin glargine in patients with type 2 diabetes. A randomised controlled trial. Ann Intern Med 138 (2003) 952-959
202. Rosenstock J., Dailey G., Massi-benedetti M., et al. Reduced hypoglycaemia risk with insulin glargine. Diabetes Care 28 (2005) 950-955
203. Raslova K., et al. Insulin determir and insulin aspart: a promising basal-bolus regimen for type 2 diabete. Diabetes Res Clin Pract 66 (2004) 193-201
204. Haak T., et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemircompared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 7 (2005) 56-64
205. Larger E., Rufat P., Dubois-Laforgue D., et al. Insuline et prise de poids : mythe ou réalité ?. Diabetes Metab Paris 27 (2001) 5523-5527
206. Messaad D., Outtas O., and Demoly P. Hype rsensibiIité aux insulines. Presse Med 33 (2004) 631-638
207. Sola-Gazagnes A, Pecquet A, Allergic à l'insuline en 2003. Journées de diabétologie Paris, Flammarion, 2004-07-30.
208. Jehle P.M., Micheler C., Jehle D.R., et al. Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens. Lancet 354 (1999) 1604-1607
209. University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: clinical implications of UGPD results. JAMA 218 (1971) 1400-1410
210. Turner R., and Holman R. Lessons from UK Prospective Diabetes Study. Diabetes research and clinical practice 28 28 suppl (1995) 5151-5157
211. UKPDS Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients withtype 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
212. Brun J.M., Cathelineau G., Charbonnel B., et al. Recommandations de l'ALFEDIAM, Mise à l'insuline du diabétique non insulino-dépendant (diabétique de type 2). Diabete & Metabolism (Paris) 21 (1995) 291-294
213. Holman R., and Turner R. Insulin therapy in type II diabetes. Diabetes Research and Clinical Practice suppl 28 (1995) S179-S184
214. Leutenegger M., Bertin E., and Grulet H. Therapeutic problems in type II diabetic patients developping insulin requirement. J Diabetes and its Complications 10 (1996) 255-260
215. Savage S., Estacio R., Jeffers B., and Schrier R. Increased complications in non insulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study. Proceedings of the Association of American Physicians 109 (1997) 181-189
216. Peters A., and Davidson M. Insulin plus a sulfony-urea agent for treating type II diabetes. Ann Intern Med 114 (1991) 45-53
217. Pugh J., Wagner M.L., Sawyer J., et al. Is combination sulfonyl-urea and insulin therapy useful in NIDDM patients?. Diabetes Care 15 (1992) 853-859
218. Johnson J., Wolf S., and Kabadi U. Efficacy of insulin and sulfonyl-urea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch intern Med 156 (1996) 259-264
219. Wright A., Felix Burden A.C., Paisey R.B., et al. Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Propective Diabetes Study (UKPDS 57). Diabetes Care 25 (2002) 330-336
220. Olsson P.O., and Landström T. Combination therapy with bedtime NPH insulin and sulphynylureas gives similar glycaemic control but lower weight gain than insulin twice daily inpatients with type 2 diabetes. Diabetes Metab 28 (2002) 272-277
221. Hayward R., Manning W., Kaplan S., Wagner E., and Greenfield S. Starting insulin therapy in patients with type II diabetes. JAMA 278 (1997) 1663-1669
222. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 24 (2001) 758-767
223. Wulffelé M.G., Kooy A., Lehert P., et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 25 (2002) 2133-2140
224. Yki-Järvinen H., Ryysy L., Nikkilä K., et al. Comparison of bedtime insulin in patients with type 2 diabetes mellitus. Ann Intern Med 130 (1999) 389-396
225. Douek J.F., Allen S.E., Ewingst P., et al. Continuing metformin when starting insulin in patients with type 2 diabetes: a double-blind randomized placebo-controlled trial. Diab Med 22 (2005) 634-640
226. Garber Al., Walden J., Wahl T., et al. Attainment of glycaemic goals in type 2 diabetes with once-twice- or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes, Obesity and Metabolism 8 (2006) 58-66
227. Janka H.U., Plewe G., Riddle M.C., et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28 (2005) 254-259
228. Raskin P., Allen E., Hollander P., et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28 (2005) 260-265
229. Davidson M.B. Starting insulin therapy in type 2 diabetic patients: does it really matter how?. Diabetes Care 28 (2005) 494-495
230. Yki-Järvinen H., Kauppinen-Mäkelin R., Tiikkainen M., et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49 (2006) 442-451
231. Kelley D.E., Bray G.A., Pi-Sunyer F.X., et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes. Diabetes Care 25 (2002) 1033-1041
232. Miles J.M., Leiter L., Hollander P., et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 25 (2002) 1123-1128
233. Hanefeld M., and Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomised, placebo-controlled trial. Diabetes Obes Metab 4 (2002) 415-423
234. Berne C., and on behalf of the Orlistat Swedish Type 2 diabetes Study Group. A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin. Diabetic Meicine 22 (2004) 612-618
235. Fujioka K., Seaton T.B., Rowe E., et al. Weight loss with sibutramine improves glycaemic control and metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2 (2000) 175-187
236. Finer N., Bloom S.R., Frost G.S., et al. Sibutramine is effective for weight loss and diabetic control in obesity with type diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2 (2000) 105-112
237. Serrano-Rios M., Melchondia N., and Moreno-Carreterot E. Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med 19 (2002) 119-124
238. Vetter R., Serra R., Fabris R., et al. Effect of sibutramine on weight management and metabolic control in type 2 diabetes. Diabetes Care 28 (2005) 942-949
239. Diabetes Prevention Program Research Group. Reduction in incidence of type 2 diabetes with lifestyle intervention or metformine. N Engl J Med 346 (2002) 393-403
240. The Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 26 (2003) 977-980
241. Chiasson J.L., Jesse R.G., Gomis R., et al., STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised Trial. Lancet 359 (2002) 2072-2077
242. Chiasson J.L., Josse R.G., Gomis R., et al., STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA 290 (2003) 486-494
243. Buchanan T.A., Xiang A.H., Peters R.K., et al. Preservation of pancreatic beta-cell function an prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51 (2002) 2796-2803
244. Togerson J.S., Hauptman J., Boldrin M.N., et al. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study. Diabetes Care 27 (2004) 155-161
245. Davies M.J., Tringham J.R., Troughton J., et al. Prevention of type 2 diabetes mellitus. A review of the evidence and its application in a UK setting. Diabet Med 21 (2004) 403-414
246. American Diabetes Association, National Institute. Diabetes and Digestive and Kidney Diseases. Prevention or delay of type 2 diabetes. Diabetes Care 27 supp 1 (2004) S47-S54
247. Hanaire-Broutin H., and Picard S. Mise en oeuvre du ≪ Diabetes Prevention Program ≫ en Europe. Diabetes Metab 29 (2003) 3516-3520
248. Scheen A.J. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 30 (2004) 487-496
249. Stratton I.M., Adler M.I., Neil A.W., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
250. Principes du dépistage du diabète de type 2. ANAES (Février 2003)
251. Doucet J. Use of antidiabetic drugs in elderly patients. Diabetes Metab 31 (2005) 5S98-5S104
252. Suivi du patient diabétique de type 2 à l'exclusion du suivi des complications. Recommandations de l'ANAES. Diabetes Metab 25 supplement 2 (1999)
253. Coster S., Gulliford M.C., Seed P.T., et al. Self-monitoring in type 2 diabetes mellitus: a meta-analysis. Diabet Med 17 (2000) 755-761
254. Coster S., Gulliford M.C., Seed P.T., et al. Monitoring blood glucose control in diabetes mellitus: a systematic review. Health Technol Assess Rep 4 (2000) 1-105
255. Welschen L.M.C., Bloemendal E., Nijpels G., et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin. Diabetes Care 28 (2005) 1510-1517
256. Welschen L.M.C., Bloemendal E., Nijpels G., et al. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insuling. The Cochrane Database of Systematic Reviews Issue 2 (2005)
257. Cramer J.A. A systematic review of adherence with medications for diabetes. Diabetes Care 27 (2004) 1218-1224
258. Pladeval M., Williams K.L., Potts L.A., et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 27 (2004) 2800-2805
259. Lau D.T., and Nan D.P. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individual with type 2 diabetes. Diabetes Care 27 (2004) 2149-2153
260. Schectman J.M., Nadkarni M.M., and Voss J.D. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care (2002) 1015-1021
261. Balkrishnan R., Rajagopolan R., Camacho F.T., et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohortstudy. Clin Ther 25 (2003) 2958-2971
262. Penfornis A. Observance médicamenteuse dans le diabète de type 2 influence des modalités du traitement médicamenteux et conséquences sur sonefficacité. Diabetes Metab 29 (2003) 3531-3537
263. McDonald H.P., Garr A.X., and Haynes R.B. Interventions to enhance patient adherence to medication prescriptions. Scientific review. JAMA 288 (2002) 2868-2879
264. Colhoun H.M., et al. The scope for cardiovascular disease with risk factor intervention among people with diabetes mellitus in England. Diabetic Medicine 1 (1999) 35-40
265. Haire-Joshu D., Glasgow R.E., and Tibbs T.L. Smoking and diabetes. Diabetes Care 22 (1999) 1887-1898
266. Fagot-Campagna A., lhaddadène K., Vallier N., Simon D., VarroudVial M., and Weill A. The ENTRED study demonstrates improvement in diabetes care process indicators among people treated with oral anti diabetic agents, France, 1998-2001. Diabetologia 46 Suppl 2 (2003) A 429-A 430
267. Schumann A. The Association between degree of nicotine dépendance and other health behaviours. Europ J Public Health 11 (2001) 450-452
268. Recommandation de bonne pratique « Stratégies médicamenteuses et non médicamenteuses de l'aide à l'arrêt du tabac » (2003), Agence française de sécurité sanitaire des produits de santé. http://www.afssaps.sante.fr
269. Recommandation de bonne pratique « Stratégies médicamenteuses et non médicamenteuses de l'aide à l'arrêt du tabac ». Alcoologie et Addictologie (2003), Agence française de sécurité sanitaire des produits de santé 25
270. a Stratégies médicamenteuses et non médicamenteuses de l'aide à l'arrêt du tabac «. Info-Respiration (2003), Agence française de sécurité sanitaire des produits de santé 19-35
271. Joseph A.M., Norman S.M., Ferry L.H., et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardia disease. N Engl J Med 33 (1996) 1792-1798
272. Hansen G., Rossing K., Jacobsen P., Jensen B., and Parving H. The acute effect of smoking on systemic hemodynamics. Kidney and endothelial functions in insulin-dependent diabetic patients with micro-albuminuria. Scand J Clin Lab Invest 56 (1996) 393-396
273. a Arrêter de fumer « (1998), Odile Jacob, Paris
274. Chatuverdi N., Jarett J., Shipley M., and Fuller J. Socioeconomic gradient in morbidity and mortality in people with diabete: cohort study findings from the White Hall Study and the WHOmultinational study of vascular disease in diabetes. BMJ 316 (1998) 100-105
275. Orth S., Ritz E., and Schrier R. The renal risk of smoking. Kidney Int 51 (1997) 1669-1677
276. Rimm E., Chan J., Stampfer M., et al. Prospective study of cigarette smoking, alcohol use and the risk of diabetes in men. BMJ 310 (1995) 555-559
277. Rimm E., Manson J., Stampfer M., et al. Cigarette smoking and the rise of diabetes in women. Am J Public Health 83 (1993) 211-214
278. Perri I., Wannamethée S., Walker M., et al. Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men. BMJ 310 (1995) 560-564
279. Facchini F., Hollenbeck C., Jeppesen J., Chen I., and Reaven G. Insulin resistance and cigarette smoking. Lancet 339 (1992) 1128-1130
280. American Diabetes Association. Smoking and diabetes. Diabetes Care 23 (2000) 93-95
281. Sawicki P.T., Didjurgeit U., Mühlhauser I., and Berger M. Behaviour therapy versus doctor's antismoking advice in diabetic patients. J Intern Med 234 (1993) 407-409
282. Canga N., de Irala J., Vara E., et al. Intervention study for smoking cessation in diabetic patients. A randomised conrolled trial in both clinical and primary care settings. Diabetes Care 23 (2000) 1455-1460
283. Recommandations et références médicales de l'ANAES. Diagnostic et traitement de l'hypertension arterille essentielle de l'adulte de 20à 80 ans. Journal des Maladies Vasculaires (paris) 23 (1998) 204-231
284. Epstein M., and Sowers J. Diabetes mellitus and hypertension. Hypertension 19 (1992) 403-418
285. Ritz E., and Stefanski A. Diabetic nephropathy un type II diabetes. Am J Kidney Disease 27 (1996) 167-194
286. Guillausseau P.J., Massin P., Charles M.A., et al. Glycaemic control and development f retinopathy un type 2 diabetes mellitus: a longitudinal study. Diabetic Medicine 15 (1998) 151-155
287. Webster M., and Scott R. What cardiologists need to know about diabetes?. Lancet 350 suppl 1 (1997) 23-28
288. Gueyffier F., Boutite F., Boissel J.P., and The INDIANA Investigators. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data frim randomized controlled trials. Ann Intern Med 127 (1997) 761-767
289. Gueyffier M.D., Ekbom T., and INDANA Committee. Efficacy of diuretics and betablockers in diabetic hypertensive patients: results from a meta-analysis. Diabetes Care 23 (2000) B65-B71
290. KPDS Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317 (1998) 713-720
291. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 317 (1998) 703-713
292. Hansson L., Zanchetti A., Carruthers S., and The HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trials. Lancet 351 (1998) 1755-1762
293. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor of calcium channel block vs diuretic.The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA 288 (2002) 2981-2997
294. Heart Outcomes prevention (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 355 (2000) 253-259
295. Lindholm L.H., Ibsen H., dahlof B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 1004-1010
296. Stratton I.M., Adler A.I., Neil H.A.W., et al. Association of glycaemia with macrovascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
297. Adler A.I., Stratton I.M., Neil H.A.W., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321 (2000) 4121-4128
298. Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
299. Société européenne d'hypertention et de cardiologie : European society of hypertension-European society of cardiology guidelines for the management of arterial hypertension - Guidelines Committee. J Hypertension 21 (2003) 1011-1053
300. Laakso M. Dyslipidemia, morbidity and mortality in non-insulindependent diabetes mellitus. Journal of Diabetes and its Complications 11 (1997) 137-141
301. UKPDS Study Group. Risk factors for coronary disease in non-insulin-dependent diabetes mellitus (UKPDS 23). BMJ 316 (1998) 823-828
302. Syvänne M., and Taskinen M.R. Lipids and lipoproteins as coronary risk factors in non-insulin dependent diabetes mellitus. Lancet 350 Suppl 1 (1997) 20-23
303. Balkan B., Eschwège E., Papoz L., et al. Risk factors for early death in non-insulin dependent diabetes and men with known glucose tolerance status. BMJ 307 (1993) 295-299
304. Dunn C., and Peters D. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49 (1995) 721-749
305. Khan M.A., St P.J.V., and Xue J.L. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosightazone inpatients with type 2 diabetes who were previouslytreated with troglitazone. Diabetes Care 25 (2002) 708-711
306. Robinson J., Folsom A., Nabulsi A., et al. Can post-menopausal hormone replacement improve plasma lipids in women with diabetes. Diabetes Care 19 (1996) 480-485
307. Guerra V., and Cannon R. Cardiovascular effects of oestrogen and lipidlowering therapies in post-menopausal women. Circulation 93 (1996) 1928-1937
308. Andersson B., Mattsson L.A., Hahn L., et al. Oestrogen replacement therapy decreases hyper androgenicity and improves glucose homeostasis and plasma lipids in post-menopausal women with insulin dependent diabetes mellitus. J Clinical Endocrinol and Metab 82 (1997) 638-643
309. Manson J.E., Hsia J., Johnson K.C., Rossouw J.E., Assaf A.R., Lasser N.L., Trevisan M., Black H.R., Heckbert S.R., Detrano R., Strickland O.L., Wong N.D., Crouse J.R., Stein E., and Cushman M. Women's Health Ini tiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 (2003) 523-534
310. Garg A., and Grundy S. Lovastatin for lowering cholesterol levels in noninsulin-dependent diabetes mellitus. N Engl J Med 318 (1988) 81-86
311. Yoshino G., Kazumi T., Iwai M., et al. Long-term treatment of hypercholesterolemic non-insulin dependent diabetics with pravastatin. Atherosclerosis 75 (1989) 67-72
312. Lintott C., Scott R., Sutherland W., et al. Comparison of simvastatin versus gemfibrozil therapy on lipid, glycemic an haemorheological parameters in type II diabetes mellitus. Diab Nutr Metab 5 (1992) 183-189
313. Ballantyne CM. Ezetimibe: efficacy ad safety in clinical trials. Eur Heart J Supplements 202;4 (suppl J): J9-J18.
314. Grundy S.M., Vega G.L., Mac G.M.E., et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Results of theassessment of diabetes control and evaluation of the efficacy of NIASPAN trial. Arch Intern Med 162 (2002) 1568-1576
315. Shepherd J., Betteridge J., Van Gaal L., and on behalf of a european consensus panel. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a Europeanconsensus panel. Current Medical Research and Opinion 21 (2005) 665-682
316. Koskinen P., Manttari M., Manninen V., et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15 (1992) 820-825
317. Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20,536 highrisk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
318. Heart Protection Study Collaborative Group. Heart protection study of cholesterol lowering with simvastatin in 5,963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
319. Sever P.S., Dahlof B., Poulter N.R., and ASCOT investigators. Prevention ofcoronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterolconcentrations, in the Anglo-Scandinavian Cardiac Outcomes TrialLipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
320. Colhoun H.M., Thomason M.J., Mackness M.I., et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Collaborative AtoRvastatin Diabetes Study (CARDS). Diabet Med 19 (2002) 201-211
321. Colhoun H.M., Betteridge D.J., Durrington P.N., et al., on behalf of the CARDS Study investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Ator vastatin Diabetes Study (CARDS): multicentre randomised placebocontrolled trial. Lancet 364 (2004) 685-696
322. Shepherd J., Blauw G.J., Murphy M.B., et al. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk.Pravastatin in elderly individuals at risk of vascular disease(PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
323. The FIELD study investigators. The need for a large-scale trial of fibrate therapyin diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
324. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus (the FIELD study): randomisedcontrolled trial. Lancet 366 (2005) 1849-1861
325. Robins S.J., Collins D., Wittes J.T., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285 (2001) 1585-1591
326. Klein R., Klein B., Moss S., et al. The Wisconsin epidemiologic study of diabetic retinopathy. III Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophtalmol 102 (1984) 527-532
327. Guillausseau P.J., Massin P., Charles M.A., et al. Glycaemic control and development of retinopathy in type 2 diabetes mellitus: a longitudinal study. Diabetic Medicine 15 (1998) 151-155
328. Nathan D., Singer E., Godine J., et al. Retinopathy in older type II diabetics. Diabetes 35 (1986) 797-801
329. UKPDS Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
330. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
331. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in japanese patients with non-insulin-dependent diabetesmellitus: a randomized prospective 6 year study. Diabetic Research and Clinical Practice 28 (1995) 103-117
332. UKPDS Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317 (1998) 713-720
333. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 317 (1998) 703-713
334. UKPDS Group (UKPDS 69). Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus. Arch Ophtalmol 122 (2004) 1631-1640
335. Gaede P., Vedel P., Larsen N., et al. (Steno). Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
336. The TIMAD study group. Ticlopidine treatment reduces the progression of non proliferative diabetic retinopathy. Arch Ophtalmol 108 (1990) 1577-1583
337. The DAMAD study group. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. Diabetes 38 (1989) 491-498
338. ETDRS report number 8. Effects of aspirin treatment on diabetic nephropathy. Ophtalmology 98 (1991) 757-765
339. vol 38. Sanchez-Thorin J.C.E.D. Ophtalmoc complications of diabetes mellitus. International ophtalmology clinics (1998), Lippincott-Raven, Philadelphia
340. Massin P., Angioi-Duprez K., Bacin F., et al. Recommandations pour le dépistage, la surveillance et la traitement de la rétinopathie diabétique. Diabetes Metab 22 (1996) 203-209
341. Wilkinson C.P., Ferris F.L., Klein R.E., Lee P.P., et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scale. Ophthalmology 110 (2003) 1677-1682
342. The Diabetic Retinopathy Study Group. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 85 (1978) 82-106
343. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 98 (1991) 766-785
344. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report number 1. Arch Opthalmol 103 (1985) 1796-1806
345. Schrier R.W., Estacio R.O., Esler A., and Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 6 (2002) 1086-1097
346. Cordonnier D.J., Zmirou D., Benhamou P.Y., et al. Epidemiology, development and treatment of end-stage renal failure in type 2 (non-insulin-dependent) diabetes mellitus. The case of mainland Franceand of overseas French territories. Diabetologia 36 (1993) 1109-1112
347. Halimi S., Zmirou D., Benhamou P.Y., et al. Premiers résultats de la seconde enquête sur l'insuffisance rénale en dialyse liée au diabète en France. Diabete & Metabolism 23 suppl 1 (1997) 20
348. Ritz E., and Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Diseases 27 (1996) 167-194
349. Biesenbach G., Janko O., and Zazgornik J. Similar rate of progression in the predialysis phase in type 1 and type 2 diabetes mellitus. Nephrol Dial Transpl 9 (1994) 1097-1102
350. Orth S., Ritz E., and Schrier R. The renal risk of smoking. Kidney Int 51 (1997) 1669-1677
351. Parving H.H., Gall M.A., Skott P., et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 41 (1992) 758-762
352. Sawicki P., Kaiser S., Heinemann L., et al. Prevalence of renal artery stenosis in diabetes mellitus. An autopsy study. J of Internal Medicine 229 (1991) 489-492
353. The Diabetes control and complications trial research group (DCCT). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 329 (1993) 956-977
354. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in japanese patients with non-insulin-dependent diabetesmellitus: a randomized prospective 6 year study. Diabetic Research and Clinical Practice 28 (1995) 103-117
355. UKPDS Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
356. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
357. Ravid M., Savin H., Jutrin I., et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and proteinuria in type II diabetic patients. Ann Intern Med 118 (1993) 577-581
358. Ravid M., Lang R., Rachmani R., and Lishner M. Long-term renoprotective effect of angiotensin converting enzyme inhibition in non-insulindependent diabetes mellitus. Ach Intern Med 12 (1996) 286-289
359. Abroad J., Siddiqui M., and Ahmad H. Effective post-ponement of diabetic nephropathy with enalapril in normotensive type diabetic patients with microalbuminuria. Diabetes Care 20 (1997) 1576-1580
360. Trevisan R., Tiengo A., and North East Italy microalbuminuria study group. Effect of low dose Ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patient. Am J Hypertension 8 (1995) 876-883
361. Lebovitz H.G., Wiegmann T., Cnaan A., et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney int 45 (1994) 150-155
362. UKPDS Group. Efficacy of atenolol and captopril in reducing risk of microvascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317 (1998) 713-720
363. UKPDS Group. Tight blood pressure control and risk of microvascular and microvascular complications in type 2 diabetes. BMJ 317 (1998) 703-713
364. Lewis E., Hunsicker L., Bain R., Rohde R., and collaborative study group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329 (1993) 1456-1462
365. Mashio G., Alberti D., Janin G., et al., angiotensin-converting enzyme inhibition in progressive renal insufficiency study group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334 (1996) 939-945
366. The GINSEN group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non diabetic nephropathy. Lancet 349 (1997) 1857-1863
367. Ruggenenti P., Perna A., Gherardi G., et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 352 (1998) 1252-1256
368. Parving H.H., Lehnert H., Brochner-Mortesen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl Med 345 (2001) 870-878
369. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Retreospective effect of the angio-tensin-receptor antogonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl Med 345 (2001) 851-860
370. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl Med 345 (2001) 861-869
371. Lam K., Cheng T., Janus E., and Pang R. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 38 (1995) 604-609
372. Casas J.P., Chua W., Loukogeorgakis S., et al. Effect of inhitibors of the renin-angiotesin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366 (2005) 2026-2033
373. Bakris G., Weir M., de Quattro V., and McMahon G. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 54 (1998) 1283-1289
374. Frimat L., Loos-Ayav C., Panescu V., et al. Early referral to a nephrologist is associated with better outcomes in type 2 diabetes patients with end-stage renal disease. Diabetes Metab 30 (2004) 67-74
375. Recommandations de l'ALFEDIAM sur l'ischémie silencieuse www.alfediam.org
376. Barzilay J., Kronmal R., Bittner V., et al. Coronary artery disease and coronary artery bypass grafting in diabetic patients aged 65 years. Am J Cardiol 74 (1994) 334-339
377. Kip K., Faxon D., Detre K., et al. Coronary angioplasty in diabetic patients. Circulation 94 (1996) 1818-1825
378. Mak Kh., and Faxon D.P. Clinical studies on coronary revascularization in patients with type 2 diabetes. For Heart J 24 (2003) 1087-1103
379. Schwartz L., Kip K.E., Frye R.L., et al. Coronary bypass graft patency in patients with diabetes in the bypass angioplasty revascularization investigation (BARI). Circulation 106 (2002) 2652-2658
380. Van belle E, Périé M, Braune D. e al. Effects of coronary stenting on vessel patency and long term clinical outcome after percutaneous coronary revacularization in diabetic patients.
381. Jonas M., Reicher-Reiss H., Boyko V., et al. Usefulness of beta-blocker therapy in patients with NIDDM and coronary artery disease. Am J Cardiol 77 (1996) 1273-1277
382. Kendall M., Lynch K., Hjalmarson A., Kjekshus J., et al. Betablockers and sudden cardiac death. Ann Intern Med 123 (1995) 358-367
383. Chen J., Marciniak T.A., Radford M.J., et al. Beta-blockers therapy for secondary prevention of myocardial infarction in elderly diabetic patients. J Am Coll Cardiol 34 (1999) 1388-1394
384. Antiplatelet Trialists'Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994) 81-106
385. Bhatt D.L., Marso S.P., Hirsh A.T., et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 90 (2002) 625-628
386. Peters R.J., Mehra S.R., Fox K.A., and the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopi dogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108 (2003) 1682-1687
387. Documentation et publications. Agence f.d.s.s.d.p.d.s.(A.). Recommandation de bonne pratique. Les stratégies thérapeutiques médicamenteuses et non médicamenteux de l'aide à l'arrêt du tabac (2003). http://www.afssaps.sante.fr.rubrique
388. Joseph A., Norman S., Ferry L., et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 335 (1996) 1792-1798
389. Malmberg K for the Digami Study Group. Prospective randomized study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetesmellitus. BMJ 314 (1997) 1512-1515
390. Malmberg K., Ryden L., Wedel H., et al., DIGAMI 2 Investigators. FASTTRACK: Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. European Heart Journal (2005)
391. Zuanetti G., Latini R., Maggioni A., et al. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Data from the GISSI-3 study. Circulation 96 (1997) 4235-4239
392. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coro nary disease: randomised, double-bind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
393. ASPECT Research Group. Effect of long-term oral anti-coagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 343 (1994) 499-503
394. The effect of diltiazem post-infarction trial research group. The effect of deltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 319 (1988) 385-392
395. Danish multicenter study group on verapamil in myocardial infarction. Verapamil in acute myocardial infarction. Am J Cardiol 54 (1984) 24 E-28 E
396. The Danish study group on verapamil in myocardial infarction. Effect of verapamil on mortality and major events after acute myocardial infarction. Am J Cardiol 66 (1990) 779-785
397. Nathan D., Meigs J., and Singer D. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet is it?. Lancet i (1997) S14S18
398. Shindler D., Kostis J., Yusuf S., et al., for the SOLVD investigators. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD). Trials and registry. Am J Cardiol 77 (1996) 1017-1020
399. Moyé L., Pfeffer M., Won B., et al., SAVE investigators. Uniformity of captopril benefice in the SAVE Study: subgroup analysis. Eur Heart J 15 suppl B (1994) 2-8
400. The digitalis investigation group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 (1997) 525-533
401. The RALES Investigator. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heartfailure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 78 (1996) 902-907
402. Packer M., Bristow M., Cohn J., et al., US carvedilol heart failure study group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996) 1349-1355
403. CIBIS II investigators and committees: The Cardiac Insufficiency Bisoprolol Study If (CIBIS II). A randomized trial. Lancet 353 (1999) 9-13
404. Atrial fibrillation investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 154 (1994) 1449-1457
405. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 308 (1994) 159-168
406. Colwell J., Bingham S., Abraira C., et al. Veteran Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: IL Effects of aspirin anddipyridamole on atherosclerotic vascular disease rates. Diabetes Care 9 (1986) 140-148
407. Becquemin J.P., et al. Effect of Ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. N Engl J Med 337 (1997) 1726-1731
408. Baudoin C., Bousser M.G., Haguenau M., et al. Secondary prevention of strokes: role of platelet anti-agregant drugs in diabetic and non-diabetic patients. Diabetic Medicine 2 (1995) 145
409. Kubin M., Wagner G., and Fugl-Meyer A.R. Epidemiology of erectile dysfunction. Int J Impot Res 15 1 (2003 Feb) 63-71
410. Susset J.G., Tessier C.D., Wincze J., Bansal S., Malhotra C., and Schwacha M.G. Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol 14l (1989) 1360-1363
411. Morales A., Surridge D.H., and Marshall P.G. Yohimbine for treatment of impotence in diabetes. N Engl J Med 305 (1981) 1221
412. Heaton J.P. Apomorphine: an update of clinical trial results. Int J Impot Res 12 (2000) 567-873
413. Boulton A.J., Selam I.L., Sweeney N.I., and Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia 44 (2001) 1296-1301
414. Sadovsky R., Miller T., Moskowitz M., and Hackett G. Three-year update of sildenafil citrate (Viagra) efficacy and safety. Int J Clin Pract 55 (2001) 115-128
415. Lepore G., and Nosari I. Efficacy of oral sildenafil in the treatment of erectile dysfunction in diabetic men with positive response to intracavernosal injection ofalprostadil. Diabetes Care 24 (2001) 409-411
416. Meuleman E., Cuzin B., Opsomer R.J., Hartmann U., Bailey M.J., Maytom M.C., Smith M.D., and Osterloh I.H. A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. BJU Int 87 (2001) 75-81
417. Burton A.J., Reynolds A., and O'Neill D. Sildenafil (Viagra) a cause o£ proliferative diabetic retinopathy?. Eye 14 (2000) 785-786
418. Freeman M.S., and Bodansky H.J. Effectiveness of treatment for impotence in diabetic men. Diabet Med 16 (1999) 1048-1049
419. Karlawish J.H., and Casarett D. Sildenafil for diabetic men with erectile dysfunction. JAMA 282 (1999) 940-941
420. Garg R., Khaishgi A., and Dandona P. Sildenafil for diabetic men with erectile dysfunction. JAMA 282 (1999) 939
421. Setter S.M., Baker D.E., Campbell R.K., and Johnson S.B. Sildenafil (Viagra) for the treatment of erectile dysfunction in men with diabetes. Diabetes Educ 25 (1999) 79-80
422. Rendell M.S., Rajfer J., Wicker P.A., and Smith M.D. Sildenafil Diabetes Study Group. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. JAMA 281 (1999) 421-426
423. Price D.E., Gingell J.C., Gepi-Attee S., Wareham K., Yates P., and Boolell M. Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med 15 (1998) 821-825
424. Bagdade J.D., Nielson K.L., and Bulger R.J. Reversible abnormalities in phagocytic function in poorly-controlled diabetic patients. Am J Med Sci 263 (1972) 451-455
425. Bistrian B.R. Hyperglycemia and infection: which is the chicken and with is the egg?. JPEN 25 (2001) 180-181
426. McMurry J.E. Wound healing with diabetes mellitus. Surg Clin North Am 64 (1984) 769-772
427. Gottrup F., and Andreassen T.T. Healing of incisional wounds in stomach and duodenum: the influence of experimental diabetes. J Surg Res 31 (1981) 61-66
428. Longstreth W.T., and Inuit T.S. High blood glucose level on hospital admission and poor neurological recovery after cardiac arrest. Ann Neurol 15 (1984) 59-62
429. Rovlias A., and Kotsou S. The influence of hyperglycemia on neurologic outcome in patients with severe head injury. Neurnsurgery 36 (1986) 1186-1191
430. Capes S.E., Hunt D., Malmberg K., Pathak P., and Gerstein H.C. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 32 (2001) 2426-2432
431. Zasslow M.A., Pearl R.G., and Shuer L.M. Hyperglycemia decreases acute neuronal ischemic changes after middle cerebral artery occlusion in cats. Stroke 20 (1989) 519-524
432. Warner M.A., Warner M.E., and Martin J.T. Ulnar neuropathy: incidence, outcome, and risk factors in sedated or anesthesied patients. Anesthesiology 81 (1994) 1332-1340
433. Capes S.E., Hunt D., Malmberg K., and Gerstein H.C. Stress hyperglycemia and increased risk ofdeath after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 355 (2000) 773-778
434. Firnary A.P., Zerr K.J., Grunkemeier G.L., and Starr A. Continuous intravenous insulin infusion reduces the incidence of deep surgical procedures. Ann Thorac Surg 67 (1999) 352-360
435. Pierre E.J., Barrow R.E., Hawkins H.K., et al. Effects of insulin on wound healing. J Trauma 44 (1998) 342-345
436. Rassias Al., Martin C.A., Arruda J., Whalen P.K., Beach M., and Yeager M.P. Insulin infusion improves neutrophil function in diabetic cardiac surgery patients. Anesth Analg 88 (1999) 1011-1016
437. Malmberg K. Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetesmellitus. Br Med J 314 (1997) 1512-1515
438. Sodi-Pallares D., Testelli M., and Fishelder F. Effects of an intravenous infusion of a potassium-insulin-glucose solution on the electrocardiographic signs of myocardial infarction. Am J Cardiol 9 (1962) 166-181
439. Fath-Ordoubadi F., and Beatt K.J. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction. An overview of randomized placebo-controlled trials. Circulation 96 (1997) 1152-1156
440. Diaz R., Paolasso E.A., Piegas L.S., et al. Metabolic modulation of acute myocardial infarction. The ECLA glucose-insulin-potassium pilot trial. Circulation 98 (1998) 2227-2234
441. Lazar H.L., Chipkin S., Philippides G., Ban Y., and Apstem C. Glucose-insulin-potassium solutions improve outcomes in diabetics who have coronary artery operations. Ann Thorac Surg 70 (2000) 145-150
442. Van Den Berghe G., Wouters P., Weekers F., Verwaest C., Bruyninckx F., Schetz M., Vlasselaers D., Ferdinande P., Lauwers P., and Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med 345 (2001) 1359-1367
443. Guha M., Bai W., Nadler J.L., and Natarajan R. Molecular mechanism of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and independent pathways. J Biol Chem 275 (2000) 17728-17739
444. Das U.N. Is insulin an anti-inflammatory molecule?. Nutrition 17 (2001) 409-413
445. Takala J., Ruokonen E., Webster P., et al. Increased mortality associated with growth hormone treatment in critically ill patients. N Engl J Med 341 (1999) 785-792
446. (éditorial associé). Belhoula M., Ciebiera J.P., De La Chapelle A., Boisseau N., Coeurveille D., and Raucoules-Aimé M. Clonidine premeditation improves metabolic control in type 2 diabetics during ophthalmic surgery. Br J Anaesth 90 (2003) 434-439
447. Venn R.M., Bryant A., Hall G.M., and Grounds R.M. Effects of dexmedetomidine on adrenocortical function, and the cardiovascular, endocrine and inflammatory responses in postoperative patientsneeding sedation in the intensive care unit. Br J Anaesth 86 (2001) 650-656
448. Salzarulo H.H., and Taylor L.A. Diabetic "stiff joint syndrome" as a cause of difficult endotrachealintubation. Anesthesiology 64 (1986) 366-368
449. Hogan K., Rusy D., and Springman S.R. Difficult laryngoscopy and diabetes mellitus. Anesth Analg 67 (1988) 1162-1165
450. Nichol H.C., and Zuch. Difficult laryngoscopy. The anterior larynx and the atlanto-occipital gap. Br J Anaesth 55 (1983) 141-144
451. Warner M.E., Contreras M.G., Warner M.A., Schroeder Dr., Munn S.R., and Maxson P.M. Diabetes mellitus and difficult laryngoscopy in renal and pancreatic transplant patient. Anesth Analg 86 (1998) 516-519
452. Valensi P., Gautier J.F., Amarengo G., Sauvanet J.P., Leutenegger M., and Attali J.R. Neuropathie autonomique chez le diabétique. Diabetes Metab 23 (1997) 89-99
453. Ralley F.E. The diabetic patient: a challenge or just a routine?. Can J Anaesth 43 (1996) 14-18
454. Burgos L.G., Hebert T.J., Assidao C., Turner L.A., Pattison C.Z., WangCheng R., and Kampine J.P. Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. Anesthesiology 70 (1989) 591-597
455. Latson T.W., Ashmore T.H., Reinhart D., Klein K.W., and Giesecke A.H. Autonomic reflex dysfunction in patients presenting for elective surgery is associated with hypotension after anesthesia induction. Anesthesiology 80 (1994) 326-337
456. Campbell I.W. Dead in bed syndrome: a new manifestation of noctural hypoglycaemia?. Diabetic Medicine 8 (1991) 3-4
457. Thordarson H., and Sovik O. Dead in bed syndrome in young diabetic patients in Norway. Diabetic Medicine 12 (1995) 782-787
458. Cox D., Gonder-Frederick L., McCall A., Kovatchev B., and Clarke W. The effects of glucose fluctuation on cognitive function and QOL: the functional costs of hypoglycaemia and hyperglycaemia among adults with type 1or type 2 diabetes. Int J Clin Pract (suppl) 129 (2002) 20-26
459. Kerr D. Continuous blood glucose monitoring: detection and prevention of hypolglycaemia. Int J Clin Pract (suppl) 123 (2001) 43-46
460. Deary I.J., Crawford J.R., and Hepbur D.A. Severe hypoglycaemia and intelligence in adult patients with insulin-treated diabetes. Diabetes 42 (1993) 341-344
461. Ryan C.M., Williams T.M., and Finegold D.N. Cognitive dysfunction in adults with type I diabetes mellitus of long duration: effects of recurrent hypoglycaemia and other chronic complications. Diabetologia 36 (1993) 329-334
462. Smelting R.K. Unique considerations in the anesthetic management of patients with diabetes mellitus. Curr Opin Anesthesiol 9 (1996) 245-246
463. Partanen J., Niskanen L., Lehtinen J., Mervaala E., Shtonen O., and Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Eng J Med 333 (1995) 89-94
464. Warner M.A., Martin J.T., Schroeder D.R., Offord K.P., and Chute C.G. Lower-extremity motor neuropathy associated with surgery performed on patients in a lithotomy position. Anesthesiology 81 (1994) 6-12
465. Warner M.A., Warner M.E., and Martin I.T. Ulnar neuropathy: incidence, outcome, and risk factors in sedated or anesthesied patients. Anesthesiology 81 (1994) 1332-1340
466. Cheney F.W., Domino K.B., Caplan R.A., and Posner K.L. Nerve injury associated with anesthesia: a closed claims analysis. Anesthesiology 90 (1999) 1062-1069
467. Hall G.M. The anaesthetic modification of the endocrine and metabolic response to surgery. Ann R Coll Surg Engl 67 (1985) 25-29
468. Shamoon H. Influence of stress and surgery on glucose regulation in diabetes: pathophysiology and management in endocrinology and anesthesia. Endocrinology and the anaesthesist. Monography in anesthesiology (1983), Elsevier ed, Amsterdam 95-122
469. Engquist A., Brandt M.R., Fernandes A., and Kehleth H. Influence of epidural analgesia on the catecholamine and cyclic AMP responses to surgery. Acta Anaesthesiol Scand 24 (1980) 17-21
470. Bromage P.R., Shibata H.R., and Willoughby H.W. Influence of prolonged epidural blockage on blood sugar and cortisol responses to operations upon the upper part of the abdomen and the thorax. Surg Gynecol Obstet 132 (1971) 1051-1056
471. Barker J.P., Robinson P.N., Vafidis G.C., Burrin J.M., Sapsed-Byrne J.M., and Hall G.M. Metabolic control of non-insulin-dependent diabetic patients undergoing cataract surgery: comparison of local and general anaesthesia. Br J Anaesth 74 (1995) 500-505
472. Kitamura A., Hoshino T., Kon T., and Ogawa R. Patients with diabetic neuropathy are at risk of a greater intraoperative reduction in core temperature. Anesthesiology 92 (2000) 1311-1318
473. McAnally H.B., and Cutter G.R. Hypothermia as a risk factor for pediatric cardiothoracic surgical site infection. Pediatr Infect Dis J 20 (2001) 459-462
474. Flores-Maldonado A., and Medina-Escobedo C.E. Mild perioperative hypothermia and the risk of wound infection. Arch Med Res 32 (2001) 227-231
475. Cattaneo C.G., Frank S.M., Hesel T.W., El-Rahmany H.K., Kim L.J., and Tran K.M. The accuracy and precision of body temperature monitoring methods during regional and general anesthesia. Anesth Analg 90 (2000) 938-945
476. Horlocker T.T., O'Driscoll S.W., and Dinapoli R.P. Recurring brachial plexus neuropathy in diabetic patient after shoulder surgery and continuous interscalene block. Anesth Analg 91 (2000) 688-690
477. Kalichman M.W., and Calcutt N.A. Local anesthetic-induced conduction block and nerve fiber injury in steptozotocin-diabetic rats. Anesthesiology 77 (1992) 941-947
478. Horlocker T.T., Cabanela M.E., and Wedel D.J. Does postoperative epidural analgesia increase the risk of peroneal nerve palsy after total knee arthroplasty?. Anesth Analg 79 (1994) 495-500
479. Rudnick M, Rose B. Radio contrast media induced acute renal failure.Up to date in Nephrology and Hypertension, February 2004-Up to date in Nephrology and Hypertension: www.uptodate.com
480. Merten G., Burgess P., Gray L., et al. Prevention of contrast induced nephropathy with sodium bicarbonate. JAMA 291 (2004) 2328-2334
481. Jannot-Lamotte M.F., and Raccah D. Corticothérapie : comment adapter le traitement antidiabétique ?. Presse Med 29 (2000) 263-266
482. Stratton I.M., Adler A.I., Neil H.A.W., et al. Association of glycaemia with macrovascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
483. Adler A.I., Stratton I.M., Neil H.A.W., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321 (2000) 412-418
484. Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393